Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial

(2014) Karim Fizazi et al.   LANCET ONCOLOGY

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial

(2013) Ethan Basch et al.   LANCET ONCOLOGY

Toward Patient-Centered Drug Development in Oncology

(2013) Ethan Basch   NEW ENGLAND JOURNAL OF MEDICINE

Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models

(2013) Bohdana Ratitch et al.   PHARMACEUTICAL STATISTICS

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

MMRM versus MI in Dealing with Missing Data—A Comparison Based on 25 NDA Data Sets

(2011) Ohidul Siddiqui   Journal of Biopharmaceutical Statistics

MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets

(2009) Ohidul Siddiqui et al.   Journal of Biopharmaceutical Statistics

Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

(2008) D. R. Berthold et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer

(2008) David Cella et al.   VALUE IN HEALTH